Børsen
Even though giants Eli Lilly and Novo Nordisk are expected to control 80 percent of the market by 2030, the market for weight loss medication is so large that there will also be room for small players like the Danish company Gubra. The biotech company’s focus on weight loss medication has generated enormous interest from investors who are awaiting trial data later this year.